万替妥单抗
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目标 | 卷曲受体 |
| 临床资料 | |
| 给药途径 | IV |
| ATC码 |
|
| 识别信息 | |
| CAS号 | 1345009-45-1 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6322H9722N1674O1988S46 |
| 摩尔质量 | 142,461.81 g·mol−1 |
万替妥单抗（INN：Vantictumab）是一种人IgG2单克隆抗体，设计用于治疗癌症。[1]
该药物由OncoMed制药公司与拜耳合作开发。[2]OncoMed于2016年获得专利，预计将于2029年到期。[3]2017年4月，拜耳终止了对万替妥单抗的许可选择。[4]
胰腺癌、非小细胞肺癌和乳腺癌的I期试验已经完成。2016年报告了三阴性乳腺癌1b期临床试验的结果，[5][6]2020年报告了胰腺癌的1b期临床试验结果。[7]
参考资料
- ^ Statement on a nonproprietary name adopted by the USAN Council (PDF). AMA. 28 Nov 2012. N12/155.
- ^ OncoMed Pre-Announces 2014 Year-End Cash Balance and Provides 2015 Guidance. 12 January 2015 [2024-03-01]. （原始内容存档于2024-03-01）.
- ^ Annual Report on Form 10-K. OncoMed Pharmaceuticals, Inc. （原始内容存档于13 January 2017）.
- ^ BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept. Reuters. 10 April 2017 [2024-03-01]. （原始内容存档于2021-05-18）.
- ^ 5.0 5.1 Finally, targeted therapies for triple-negative breast cancer. Medical Xpress. June 2016 [2024-03-01]. （原始内容存档于2024-01-08）.
- ^ Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Research and Treatment. November 2020, 184 (1): 53–62. PMC 7572714
. PMID 32803633. doi:10.1007/s10549-020-05817-w.
- ^ Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Investigational New Drugs. June 2020, 38 (3): 821–830. PMC 7211194 . PMID 31338636. doi:10.1007/s10637-019-00824-1.
 | 这是一篇与药学相关的小作品。您可以通过编辑或修订扩充其内容。 |